MDAI vs. NMTC, MODD, FEMY, LUCD, CODX, LNSR, ICU, IINN, GBS, and NEPH
Should you be buying Spectral AI stock or one of its competitors? The main competitors of Spectral AI include NeuroOne Medical Technologies (NMTC), Modular Medical (MODD), Femasys (FEMY), Lucid Diagnostics (LUCD), Co-Diagnostics (CODX), LENSAR (LNSR), SeaStar Medical (ICU), Inspira Technologies Oxy B.H.N. (IINN), GBS (GBS), and Nephros (NEPH). These companies are all part of the "surgical & medical instruments" industry.
NeuroOne Medical Technologies (NASDAQ:NMTC) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.
NeuroOne Medical Technologies has higher earnings, but lower revenue than Spectral AI.
In the previous week, Spectral AI had 7 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 8 mentions for Spectral AI and 1 mentions for NeuroOne Medical Technologies. Spectral AI's average media sentiment score of 1.00 beat NeuroOne Medical Technologies' score of 0.46 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.
Spectral AI has a net margin of 0.00% compared to Spectral AI's net margin of -478.41%. NeuroOne Medical Technologies' return on equity of 0.00% beat Spectral AI's return on equity.
NeuroOne Medical Technologies received 62 more outperform votes than Spectral AI when rated by MarketBeat users. However, 100.00% of users gave Spectral AI an outperform vote while only 71.59% of users gave NeuroOne Medical Technologies an outperform vote.
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 67.1% of Spectral AI shares are held by institutional investors. 7.5% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 56.7% of Spectral AI shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
NeuroOne Medical Technologies has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Spectral AI has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.
NeuroOne Medical Technologies currently has a consensus target price of $2.20, suggesting a potential upside of 94.69%. Spectral AI has a consensus target price of $4.00, suggesting a potential upside of 116.22%. Given NeuroOne Medical Technologies' higher possible upside, analysts clearly believe Spectral AI is more favorable than NeuroOne Medical Technologies.
Summary
Spectral AI beats NeuroOne Medical Technologies on 9 of the 14 factors compared between the two stocks.
Get Spectral AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spectral AI Competitors List
Related Companies and Tools
